This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sbi Biotech Co., Ltd.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Megumi Okuyama: Innovator in Immune-Mediated Disorder Treatments
Introduction
Megumi Okuyama is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic solutions for immune-mediated disorders. Her innovative work has garnered attention for its potential to improve treatment options for various inflammatory diseases.
Latest Patents
Megumi Okuyama holds a patent for "TLR inhibitory oligonucleotides and their use." This patent describes inhibitory oligonucleotides with partial phosphorothioation that exhibit reduced toxicity while effectively blocking NF-kB activation induced by TLR9 and TLR7/8 agonists. The oligonucleotides inhibit the production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa). Additionally, they prevent interferon (IFN) production from human PBMC induced by TLR9 agonists. These oligonucleotides have the potential to serve as remedies for immune-mediated disorders, including rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes, and inflammatory cytokine-mediated diseases.
Career Highlights
Megumi Okuyama is associated with Sbi Biotech Co., Ltd., where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, focusing on innovative solutions for complex health issues.
Collaborations
Throughout her career, Megumi has collaborated with notable colleagues, including Eiji Esashi and Koji Ishida. These partnerships have contributed to the advancement of her research and the successful development of her patented technologies.
Conclusion
Megumi Okuyama's contributions to the field of biotechnology, particularly through her patent on TLR inhibitory oligonucleotides, highlight her role as an innovator in the treatment of immune-mediated disorders. Her work continues to pave the way for new therapeutic approaches that could significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile